In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Hikma Pharmaceuticals PLC

www.hikma.com

Latest From Hikma Pharmaceuticals PLC

Launches Let Hikma Cope With Competition On US Injectables

A stream of launches, including of vancomycin as its 100th injectable medicine in the US, is helping Hikma’s Injectables business segment to more than offset the effects of increased competition.
Launches United States

Hikma Is Halted By US Everolimus Method-Of-Use Patent

While a Delaware district court incorrectly held Hikma’s West-Ward to a heightened standard on motivation to combine prior art, that error did not prove fatal to its decision to uphold the validity of a US patent protecting Novartis’s Afinitor everolimus treatment for RCC until May 2026.

 


Intellectual Property Cancer

Vectura Prevails In US Litigation Over GSK’s Ellipta

Vectura has won an award of almost $90m after convincing a Delaware jury that GSK’s Ellipta respiratory range infringed one of its US patents. The firm currently has a development deal with Hikma for generic versions.

Legal Issues Generic Drugs

US PTO's Patent Eligibility Guidance Draws Industry Plaudits, Request For More Specifics

BIO, PhRMA, Novartis, Amgen, and Genentech suggest revisions to guidance on hot-button issue of subject matter patent eligiblity; patent owners group says 'best approach' is to enact legislation to restore patent eligibility law.

Intellectual Property Legal Issues
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Generic Drugs
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Parent & Subsidiaries
  • Hikma Pharmaceuticals PLC
  • Senior Management
  • Said Darwazah, Chmn. & CEO
    Khalid Nabilsi, CFO
    Bassam Kanaan, Chief Strategy & Corp. Dev. Officer
  • Contact Info
  • Hikma Pharmaceuticals PLC
    Phone: (44) 20 7399 2760
    1 New Burlington Pl.
    London, W1S 2HR
    UK
Advertisement
Advertisement
UsernamePublicRestriction

Register